Botulinum toxin type A as a migraine preventive treatment

Headache

Volumn 40, Issue 6, 2000, Pages 445-450

  Silberstein, Stephen ^a   Mathew, Ninan ^d   Saper, Joel ^b   Jenkins, Stephen ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Michigan Hd Pain Neurologic Inst   (United States)

^c ALLERGAN INC   (United States)

^d NONE

Author keywords

Headache; Myogenic pain

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INJECTION SITE; MALE; MIGRAINE; PRIORITY JOURNAL; PTOSIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEAD; HUMANS; INCIDENCE; INJECTIONS, INTRAMUSCULAR; MEDICAL RECORDS; MIDDLE AGED; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS;

EID: 0033917504     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2000.00066.x     Document Type: Article

References (13)

1. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213-1218.
2. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616-623.
3. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306-1310.
4. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512-515.
5. Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med. 1998;338:217-220.
6. Annese V, Basciani M, Borrelli O, Leandro G. Simone P, Andriulli A. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve. 1998;21:1540-1542.
7. Naumann M, Flachenecker P, Brocker EB, Toyka KV, Reiners K. Botulinum toxin for palmar hyperhidrosis. Lancet. 1997;349:252.
8. Knusel B, Grant M, Loesser JD, et al. Intramuscular injection of botulinum toxin type A (BOTOX®) in chronic low back pain associated with muscle spasm. Poster presented at: American Pain Society Meeting; November 1998; San Diego, Calif. Poster 672.
9. Binder W, Brin MF, Blitzer A, Schenrock L, Diamond B. Botulinum toxin type A (BTX-A) for migraine: an open label assessment [abstract]. Mov Disord. 1998;13(suppl 2):241(P4-104).
10. Davidoff RA. Migraine: Manifestations, Pathogenesis, and Management. Philadelphia, Pa: FA Davis Co; 1995.
11. Borodic GE, Ferrante RJ, Pearce LB, Alderson K. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J, Hallett M, eds. Therapy With Botulinum Toxin. New York, NY: Marcel and Dekker, Inc; 1994:119-158.
12. Tfelt-Hansen P, Lous I, Olesen J. Prevalence and significance of muscle tenderness during common migraine attacks. Headache. 1981;21:49-54.
13. Hohne-Zell B, Galler A, Schepp W, Gratzl M, Prinz C. Functional importance of synaptobrevin and SNAP-25 during exocytosis of histamine by rat gastric enterochromaffin-like cells. Endocrinology. 1997; 138:5518-5526.